Impact of Concomitant Medication Use on Treatment Outcomes in Patients with Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Introduction Concomitant medications such as statins, aspirin, and metformin may modulate immune responses and influence outcomes with immune checkpoint inhibitors (ICIs). Their impact in advanced renal cell carcinoma (aRCC) remains unclear. Methods We conducted a retrospective study of 400 patients with aRCC treated with ICIs at Winship Cancer Institute of Emory University from 2018 to 2023. Baseline medication use, defined as active prescription at the time of ICI initiation, was documented. Clinical end points included overall survival (OS), progression-free survival (PFS), and disease control rate (DCR). Kaplan-Meier estimates, Cox proportional hazards models, and multivariable regression were used to assess associations between medication use and outcomes. Results At baseline, 42.5% of patients were on statins, 34.5% on aspirin, and 12.3% on metformin. Median follow-up was 43.0 months. Statin use was associated with improved DCR (odds ratio, 1.85; p = 0.008), with a positive trend observed for PFS (hazard ratio [HR], 0.81; p = 0.071) in univariable analysis. However, no significant independent associations were observed in multivariable models for overall survival (HR, 0.92; p = 0.629), PFS (HR, 0.90; p = 0.410), or DCR (odds ratio, 1.48; p = 0.119). Aspirin and metformin use were not significantly associated with outcomes in univariable analyses and were excluded from multivariable models. Conclusion In this large real-world cohort, concomitant statin, aspirin, and metformin use did not independently influence survival or response outcomes in patients with aRCC receiving ICIs. Although statin use was univariably associated with a higher disease control rate, this effect did not persist after multivariable adjustment. These findings indicate that these common medications are unlikely to have a strong independent impact on immunotherapy outcomes in this population. Graphical Abstract

Authors

Institutions

Publication Details

Journal
Journal of Immunotherapy and Precision Oncology
Published
2026-11-20
DOI
https://doi.org/10.36401/jipo-26-13
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Impact of Concomitant Medication Use on Treatment Outcomes in Patients with Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Umut Akova, Viraj A. Master, Greta Russler McClintock, Yuan Liu et al.
3 links
Journal of Immunotherapy and Precision Oncology
Renal cell carcinoma treatment
article

Impact of Concomitant Medication Use on Treatment Outcomes in Patients with Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Umut Akova, Viraj A. Master, Greta Russler McClintock, Yuan Liu, Ahmet Yildirim, Bradley Curtis Carthon, Mehmet Asım Bilen, Jacob E. Berchuck, Jacqueline Theresa Brown, Bassel Nazha, Jordan Alana Ciuro, Sarah E. Caulfield, Omer Kucuk, Caitlin Hartman, Shahid Sattar Ahmed, Jillian C. Thompson, Yash Jani
article en

Abstract

Introduction Concomitant medications such as statins, aspirin, and metformin may modulate immune responses and influence outcomes with immune checkpoint inhibitors (ICIs). Their impact in advanced renal cell carcinoma (aRCC) remains unclear. Methods We conducted a retrospective study of 400 patients with aRCC treated with ICIs at Winship Cancer Institute of Emory University from 2018 to 2023. Baseline medication use, defined as active prescription at the time of ICI initiation, was documented. Clinical end points included overall survival (OS), progression-free survival (PFS), and disease control rate (DCR). Kaplan-Meier estimates, Cox proportional hazards models, and multivariable regression were used to assess associations between medication use and outcomes. Results At baseline, 42.5% of patients were on statins, 34.5% on aspirin, and 12.3% on metformin. Median follow-up was 43.0 months. Statin use was associated with improved DCR (odds ratio, 1.85; p = 0.008), with a positive trend observed for PFS (hazard ratio [HR], 0.81; p = 0.071) in univariable analysis. However, no significant independent associations were observed in multivariable models for overall survival (HR, 0.92; p = 0.629), PFS (HR, 0.90; p = 0.410), or DCR (odds ratio, 1.48; p = 0.119). Aspirin and metformin use were not significantly associated with outcomes in univariable analyses and were excluded from multivariable models. Conclusion In this large real-world cohort, concomitant statin, aspirin, and metformin use did not independently influence survival or response outcomes in patients with aRCC receiving ICIs. Although statin use was univariably associated with a higher disease control rate, this effect did not persist after multivariable adjustment. These findings indicate that these common medications are unlikely to have a strong independent impact on immunotherapy outcomes in this population. Graphical Abstract

Journal of Immunotherapy and Precision OncologyVol. 10(1)
Emory University (US), Augusta University (US), Winship Cancer Institute (US)
Good health and well-being
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon